Ocular Therapeutix OTX-TP

GPTKB entity

Properties (61)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:activeDuring dexamethasone
gptkbp:administrativeDivision up to 30 days
once per eye
conjunctival sac
intraocular insertion
gptkbp:applicationStatus approved
gptkbp:clinicalTrials gptkb:United_States
gptkb:Ocular_Therapeutix,_Inc.
available online
positive
Phase 3
reduces inflammation
Phase 1, Phase 2, Phase 3
randomized controlled trial
demonstrated efficacy
published in medical journals
various sites
improved symptoms
recommended for use
ocular surgery recovery
gptkbp:community_service efficacy and safety
available through pharmacies
gptkbp:communityPartnerships none disclosed
gptkbp:customerFeedback generally positive
gptkbp:delivers insert
gptkbp:developedBy gptkb:Ocular_Therapeutix,_Inc.
gptkbp:drugInterdiction 2018-06-28
corticosteroid
insertable hydrogel
stable for 30 days
sustained-release technology
gptkbp:exportMarkets ongoing
gptkbp:formulation sustained-release hydrogel
gptkbp:hasCompetitors other dry eye treatments
gptkbp:hasPopulation adults
gptkbp:healthcare high
ongoing
https://www.w3.org/2000/01/rdf-schema#label Ocular Therapeutix OTX-TP
gptkbp:impact up to 30 days
reduced symptoms of dry eye
single insertion
gptkbp:mandates post-surgical inflammation
gptkbp:market 2018
achieved
gptkbp:marketedAs brand name Dextenza
gptkbp:patentStatus patented
gptkbp:productionCompany commercialized
gptkbp:purpose ocular inflammation management
gptkbp:regulatoryBody gptkb:FDA
gptkbp:research private investment
gptkbp:research_areas ophthalmology
gptkbp:researchAreas sustained drug delivery systems
gptkbp:researchFocus ocular drug delivery
gptkbp:researchInterest peer-reviewed journals
none disclosed
gptkbp:route topical
gptkbp:safetyFeatures generally well tolerated
gptkbp:sideEffect eye irritation
gptkbp:triggerType anti-inflammatory
gptkbp:usedFor treatment of dry eye disease